AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35076863 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Living Partnerships to Prevent Cancer (HELP PC) intervention
Number of subjects: 0
Study 35076931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenous dose
Number of subjects: 78
Study 35076931 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predictions for ondansetron transfer into breast milk
Number of subjects: 78
Study 35076939 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical ctDNA detection
Number of subjects: 119
Study 35076939 — intervention group
Group type: EXPERIMENTAL
Intervention: First postsurgical ctDNA detection
Number of subjects: 119
Study 35076939 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal ctDNA monitoring
Number of subjects: 119
Study 35076939 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial ctDNA detection
Number of subjects: 119
Study 35077032 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpaced breathing
Number of subjects: 59
Study 35077032 — intervention group
Group type: COMPARATOR
Intervention: Paced breathing (0.25 Hz, 15 breaths per minute)
Number of subjects: 59
Study 35077897 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with psychological evaluations preoperatively and at 6 months post-surgery.
Number of subjects: 77
Study 35077897 — intervention group
Group type: COMPARATOR
Intervention: Control group with satisfactory joint range of motion (group B) after rotator cuff repair.
Number of subjects: 77
Study 35078125 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sNfL
Number of subjects: 58
Study 35078125 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-fold difference in baseline sNfL (from 10 to 20 pg/mL)
Number of subjects: 58
Study 35078125 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-fold increase in sNfL level from the first measurement
Number of subjects: 58
Study 35078125 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal increases in sNfL for patients with lower baseline values (<10 pg/mL)
Number of subjects: 58
Study 35078125 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and longitudinal changes in sNfL
Number of subjects: 58
Study 35078345 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular cell carcinoma
Number of subjects: 0
Study 35078345 — intervention group
Group type: EXPERIMENTAL
Intervention: Hurthle cell carcinoma
Number of subjects: 0
Study 35078538 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS) for five minutes daily for 26 weeks.
Number of subjects: 7
Study 35078739 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 60mg twice weekly
Number of subjects: 134
Study 35078840 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person interventions for tobacco or e-cigarette cessation
Number of subjects: 0
Study 35078873 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with poor health
Number of subjects: 441
Study 35078873 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with low preparedness
Number of subjects: 441
Study 35078873 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse caregiver health
Number of subjects: 441
Study 35078873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low preparedness
Number of subjects: 441
Study 35078873 — intervention group
Group type: EXPERIMENTAL
Intervention: High burden
Number of subjects: 441
Study 35078873 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver factors
Number of subjects: 441
Study 35078972 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib and azacitidine (ENA + AZA)
Number of subjects: 0
Study 35078972 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (VEN)
Number of subjects: 0
Study 35078975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines and kynurenine metabolites in the 2nd trimester
Number of subjects: 114
Study 35078975 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1β and IL-6 levels
Number of subjects: 114
Study 35079567 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 1
Study 35079778 — intervention group
Group type: EXPERIMENTAL
Intervention: SphygmoCor XCEL PWA device (ATCOR, Naperville, IL)
Number of subjects: 136
Study 35079778 — intervention group
Group type: COMPARATOR
Intervention: Pressure catheters
Number of subjects: 136
Study 35079778 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid-state high-fidelity catheters (Millar, Houston, TX)
Number of subjects: 136
Study 35079784 — intervention group
Group type: EXPERIMENTAL
Intervention: INO-4800 (0.5 mg, 1.0 mg, and 2.0 mg)
Number of subjects: 120
Study 35079784 — intervention group
Group type: EXPERIMENTAL
Intervention: INO-4800 (2.0 mg)
Number of subjects: 120
Study 35080038 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical approach to combining multiple measures of adherence
Number of subjects: 0
Study 35080038 — intervention group
Group type: COMPARATOR
Intervention: Self-report adherence measurement
Number of subjects: 0
Study 35080076 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for sinonasal malignancies
Number of subjects: 400
Study 35080147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (IL-6, TNF-α, IL-8) in cachectic patients
Number of subjects: 1277
Study 35080147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (IL-6) in cachectic vs non-cachectic patients
Number of subjects: 1277
Study 35080147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (Leptin, interferon-γ, IL-1β, IL-10, adiponectin, ghrelin)
Number of subjects: 1277
Study 35080147 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1277
Study 35080190 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 0
Study 35080190 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus enzalutamide
Number of subjects: 0
Study 35080267 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised foot orthoses (CFOs)
Number of subjects: 1058
Study 35080267 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses (PFOs)
Number of subjects: 1058
Study 35080454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative MRI metrics
Number of subjects: 0
Study 35080495 — intervention group
Group type: EXPERIMENTAL
Intervention: BWSS with perturbation (BWSS-P)
Number of subjects: 29
Study 35080495 — intervention group
Group type: COMPARATOR
Intervention: BWSS (control)
Number of subjects: 29
Study 35080495 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (historical comparison)
Number of subjects: 29
Study 35080495 — intervention group
Group type: COMPARATOR
Intervention: BWSS groups (both)
Number of subjects: 29
Study 35080499 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAR-008
Number of subjects: 130
Study 35080499 — intervention group
Group type: COMPARATOR
Intervention: reSET-O
Number of subjects: 130
Study 35080500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounce Back program (stress management and resiliency program delivered via videoconference)
Number of subjects: 72
Study 35080500 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 72
Study 35080500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounce Back program
Number of subjects: 72
Study 35080505 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCO-TreC mobile app for patients and web-based dashboard for health care professionals
Number of subjects: 40
Study 35080505 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCO-TreC mobile app for patients
Number of subjects: 40
Study 35080505 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCO-TreC system
Number of subjects: 40
Study 35080734 — intervention group
Group type: EXPERIMENTAL
Intervention: pCASL (pseudo-continuous arterial spin labelling)
Number of subjects: 54
Study 35080773 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 1336
Study 35080773 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 1336
Study 35080771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalomedullary nails
Number of subjects: 10979
Study 35080914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 35081061 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 ICU admissions
Number of subjects: 428
Study 35081092 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprojected bone SPECT/CT (RBS)
Number of subjects: 131
Study 35081092 — intervention group
Group type: COMPARATOR
Intervention: Planar bone scintigraphy (BS)
Number of subjects: 131
Study 35081094 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body resistance exercise three times a week for 8 weeks
Number of subjects: 20
Study 35081094 — intervention group
Group type: COMPARATOR
Intervention: Untrained state (REST)
Number of subjects: 20
Study 35081094 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained state (T)
Number of subjects: 20
Study 35081106 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment for school attendance problems (SAPs)
Number of subjects: 152
Study 35081237 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal oxygenation targets (SpO2 96%)
Number of subjects: 15
Study 35081237 — intervention group
Group type: COMPARATOR
Intervention: Conservative oxygenation targets (SpO2 88% - 92%)
Number of subjects: 15
Study 35081293 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (Moderna) at a dose of 100 μg
Number of subjects: 458
Study 35081293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5×10^10 viral particles
Number of subjects: 458
Study 35081293 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2
Number of subjects: 458
Study 35081293 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous boosters
Number of subjects: 458
Study 35081293 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous boosters
Number of subjects: 458
Study 35081293 — intervention group
Group type: COMPARATOR
Intervention: Ad26.COV2.S-boosted subgroup
Number of subjects: 458
Study 35081314 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-related energy expenditure (AEE)
Number of subjects: 0
Study 35081314 — intervention group
Group type: EXPERIMENTAL
Intervention: Body size and walking economy (net V̇o)
Number of subjects: 0
Study 35081550 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal/dietary supplements (HDS)
Number of subjects: 277
Study 35081550 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobials
Number of subjects: 277
Study 35081550 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall transplant-free survival
Number of subjects: 277
Study 35081550 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 277
Study 35081732 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive SARS-CoV-2 vaccination (inactivated virus vaccine)
Number of subjects: 0
Study 35081732 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35082313 — intervention group
Group type: EXPERIMENTAL
Intervention: Photovoltaic substitute of the photoreceptors implanted subretinally
Number of subjects: 5
Study 35082386 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 25 ≤ BMI ≤ 32
Number of subjects: 66
Study 35082386 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI > 32
Number of subjects: 66
Study 35082386 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI < 25
Number of subjects: 66
Study 35082514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor treatment
Number of subjects: 100
Study 35082572 — intervention group
Group type: EXPERIMENTAL
Intervention: LAR subtype after standard adjuvant or neoadjuvant chemotherapy
Number of subjects: 124
Study 35082572 — intervention group
Group type: COMPARATOR
Intervention: Non-LAR disease after standard adjuvant or neoadjuvant chemotherapy
Number of subjects: 124
Study 35083234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral conbercept injection
Number of subjects: 74
Study 35083234 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal conbercept injection
Number of subjects: 74
Study 35083234 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C plus pan-retinal photocoagulation (PRP)
Number of subjects: 74
Study 35083234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral group
Number of subjects: 74
Study 35083365 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine
Number of subjects: 1000
Study 35083774 — intervention group
Group type: EXPERIMENTAL
Intervention: Approved dupilumab doses
Number of subjects: 612
Study 35083774 — intervention group
Group type: EXPERIMENTAL
Intervention: Other studied dupilumab doses
Number of subjects: 612
Study 35083774 — intervention group
Group type: EXPERIMENTAL
Intervention: All dupilumab doses
Number of subjects: 612
Study 35083774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study 35083809 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact on patients
Number of subjects: 239
Study 35083809 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact on caregivers
Number of subjects: 239
Study 35083809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of COVID-19
Number of subjects: 239
Study 35083809 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit finding due to the pandemic
Number of subjects: 239
Study 35083809 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological functioning
Number of subjects: 239
Study 35083809 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care utilization
Number of subjects: 239
Study 35084153 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with myocarditis
Number of subjects: 16319
Study 35084153 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with myocarditis
Number of subjects: 16319
Study 35084153 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myocarditis (both sexes)
Number of subjects: 16319
Study 35084153 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 21-40 years with myocarditis
Number of subjects: 16319
Study 35084335 — intervention group
Group type: EXPERIMENTAL
Intervention: CutC/D inhibitors (non-lethal bacterial choline TMA lyase inhibitors)
Number of subjects: 0
Study 35084335 — intervention group
Group type: COMPARATOR
Intervention: Ethanol consumption
Number of subjects: 0
Study 35084335 — intervention group
Group type: EXPERIMENTAL
Intervention: CutC/D inhibitors
Number of subjects: 0
Study 35084335 — intervention group
Group type: COMPARATOR
Intervention: TMA levels
Number of subjects: 0
Study 35084435 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (selective ETA receptor antagonist)
Number of subjects: 26
Study 35084435 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-788 (selective ETB antagonist)
Number of subjects: 26
Study 35084435 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemia alone
Number of subjects: 26
Study 35084544 — intervention group
Group type: EXPERIMENTAL
Intervention: ExoDx Prostate IntelliScore (EPI) urine test
Number of subjects: 2066
Study 35084544 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI score <15.6
Number of subjects: 2066
Study 35084544 — intervention group
Group type: COMPARATOR
Intervention: Multivariate risk calculators (ERSPC and PCPT)
Number of subjects: 2066
Study 35084584 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implants placed in patients on HDAR (bisphosphonates and denosumab)
Number of subjects: 27
Study 35084584 — intervention group
Group type: EXPERIMENTAL
Intervention: Abutment operation performed 4 months after implant placement
Number of subjects: 27
Study 35084649 — intervention group
Group type: EXPERIMENTAL
Intervention: PACU delirium present
Number of subjects: 222
Study 35084882 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Childhood Experiences (ACEs)
Number of subjects: 0
Study 35084882 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner's individual and relationship functioning
Number of subjects: 0
Study 35085007 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 20
Study 35085462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) administered to 15 patients
Number of subjects: 23
Study 35085462 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 patients not receiving TCZ)
Number of subjects: 23
Study 35085538 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide-polymorphism-based cell-free DNA screening for trisomy 21
Number of subjects: 20194
Study 35085538 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide-polymorphism-based cell-free DNA screening for trisomy 18
Number of subjects: 20194
Study 35085538 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide-polymorphism-based cell-free DNA screening for trisomy 13
Number of subjects: 20194
Study 35085538 — intervention group
Group type: EXPERIMENTAL
Intervention: No-call results after first draw
Number of subjects: 20194
Study 35085538 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated cell-free DNA algorithm
Number of subjects: 20194
Study 35086120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-focus soft contact lenses (DFCL; MiSight 1 day)
Number of subjects: 85
Study 35086120 — intervention group
Group type: COMPARATOR
Intervention: Control contact lens (Proclear 1 day)
Number of subjects: 85
Study 35086120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-focus soft contact lenses (DFCL; MiSight 1 day) after switching from control
Number of subjects: 85
Study 35086123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysophosphatidylcholine 16:0 (LPC16:0)
Number of subjects: 0
Study 35086123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injections of LPC16:0
Number of subjects: 0
Study 35086123 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIC3 channels
Number of subjects: 0
Study 35086148 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 107
Study 35086148 — intervention group
Group type: COMPARATOR
Intervention: Aromatase Inhibitors (AIs)
Number of subjects: 107
Study 35086483 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension strength (KES) testing
Number of subjects: 100
Study 35086483 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) testing
Number of subjects: 100
Study 35086481 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct antiviral agents
Number of subjects: 559
Study 35086481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virological response
Number of subjects: 559
Study 35086504 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized adherence enhancement intervention combined with long-acting injectable antipsychotic medication (LAI)
Number of subjects: 19
Study 35086504 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable antipsychotic medication (LAI)
Number of subjects: 19
Study 35086561 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFJ morphological parameters (S, Sτ)
Number of subjects: 0
Study 35086561 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFJ morphological parameters (Sτ, Sυ, S)
Number of subjects: 0
Study 35086561 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFJ morphological parameters (Sτ)
Number of subjects: 0
Study 35086561 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFJ morphological parameters (Sφ)
Number of subjects: 0
Study 35086719 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic subtype GenS1 (67%)
Number of subjects: 116
Study 35086719 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic subtype GenS2 (24%)
Number of subjects: 116
Study 35086719 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic subtypes: luminal-a and luminal-b (40%)
Number of subjects: 116
Study 35086719 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic subtype: stroma-rich (24%)
Number of subjects: 116
Study 35086719 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic subtype: basal/squamous (23%)
Number of subjects: 116
Study 35086719 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic subtype: nonspecified (12%)
Number of subjects: 116
Study 35086897 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35086918 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-GWAS predictive power for AF based on Japanese GWAS
Number of subjects: 6358
Study 35086918 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-GWAS predictive power for AF based on European GWAS
Number of subjects: 6358
Study 35086918 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-GWAS predictive power for AF based on multiethnic GWAS
Number of subjects: 6358
Study 35086919 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients with cardiomyopathy
Number of subjects: 1236
Study 35086919 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cardiomyopathy in the Heart Hive COVID-19 study
Number of subjects: 1236
Study 35086919 — intervention group
Group type: EXPERIMENTAL
Intervention: National cardiomyopathy-related hospital admissions
Number of subjects: 1236
Study 35086946 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP-A2M10 SPEAR T cells
Number of subjects: 11
Study 35086949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with paclitaxel
Number of subjects: 0
Study 35086949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with capecitabine
Number of subjects: 0
Study 35086949 — intervention group
Group type: COMPARATOR
Intervention: Curative-intent dose-dense anthracycline and cyclophosphamide (ddAC)
Number of subjects: 0
Study 35086949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with paclitaxel or capecitabine
Number of subjects: 0
Study 35087031 — intervention group
Group type: EXPERIMENTAL
Intervention: WX-0593 (Iruplinalkib)
Number of subjects: 153
Study 35087084 — intervention group
Group type: EXPERIMENTAL
Intervention: Early booster Vi-DT vaccine
Number of subjects: 285
Study 35087084 — intervention group
Group type: EXPERIMENTAL
Intervention: Late booster Vi-DT vaccine
Number of subjects: 285
Study 35087084 — intervention group
Group type: COMPARATOR
Intervention: Comparison of early and late booster groups
Number of subjects: 285
Study 35087097 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger participants (younger than 60)
Number of subjects: 60